Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Documenti analoghi

• Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
  di: Maker, Ajay V., et al.
  Pubblicazione: (2005)
• Inability to Immunize Patients with Metastatic Melanoma Using Plasmid DNA Encoding the gp100 Melanoma-Melanocyte Antigen
  di: Rosenberg, Steven A., et al.
  Pubblicazione: (2003)
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
  di: Dudley, Mark E., et al.
  Pubblicazione: (2002)
• Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class Ii-Restricted Peptides from Melanoma-Associated Antigens
  di: Phan, Giao Q., et al.
  Pubblicazione: (2003)
• Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
  di: Attia, Peter, et al.
  Pubblicazione: (2005)